TY - JOUR
T1 - Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy
AU - Oba, Shigeo
AU - Teranishi, Takao
AU - Matsumura, Kazuyasu
AU - Kumon, Masanobu
AU - Kojima, Daijiro
AU - Fujiwara, Eiji
AU - Nakao, Kazutaka
AU - Kuwahara, Kiyonori
AU - Murayama, Kazuhiro
AU - Pareira, Eriel Sandika
AU - Yamada, Seiji
AU - Joko, Masahiro
AU - Nakae, Shunsuke
AU - Muto, Jun
AU - Nishiyama, Yuya
AU - Adachi, Kazuhide
AU - Sasaki, Hikaru
AU - Abe, Masato
AU - Hasegawa, Mitsuhiro
AU - Hirose, Yuichi
N1 - Publisher Copyright:
© 2025. The Author(s).
PY - 2025/1/11
Y1 - 2025/1/11
N2 - Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.
AB - Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.
KW - Glioblastoma
KW - Karnofsky Performance Status
KW - MGMT
KW - Radiotherapy
KW - Temozolomide
KW - Tumor size
UR - http://www.scopus.com/inward/record.url?scp=85215354845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215354845&partnerID=8YFLogxK
U2 - 10.1038/s41598-025-85339-x
DO - 10.1038/s41598-025-85339-x
M3 - Article
C2 - 39799218
AN - SCOPUS:85215354845
SN - 2045-2322
VL - 15
SP - 1750
JO - Scientific reports
JF - Scientific reports
IS - 1
ER -